Disease Activity, Physical Function, and Radiographic Progression After Longterm Therapy with Adalimumab Plus Methotrexate: 5-Year Results of PREMIER

REFERENCES

1. 1.↵
   1. van der Heijde DM

   . Joint erosions and patients with early rheumatoid arthritis. Br J Rheumatol 1995;34 Suppl 2:74–8.

   OpenUrlPubMed
2. 2.↵
   1. Lindqvist E,
   2. Jonsson K,
   3. Saxne T,
   4. Eberhardt K

   . Course of radiographic damage over 10 years in a cohort with early rheumatoid arthritis. Ann Rheum Dis 2003;62:611–6.

   OpenUrlAbstract/FREE Full Text
3. 3.↵
   1. Emery P,
   2. Breedveld FC,
   3. Dougados M,
   4. Kalden JR,
   5. Schiff MH,
   6. Smolen JS

   . Early referral recommendation for newly diagnosed rheumatoid arthritis: evidence based development of a clinical guide. Ann Rheum Dis 2002;61:290–7.

   OpenUrlAbstract/FREE Full Text
4. 4.↵
   1. Jamal S,
   2. Patra K,
   3. Keystone EC

   . Response to adalimumab in patients with early versus established rheumatoid arthritis: DE019 randomized controlled trial subanalysis. Clin Rheumatol 2009;28:413–9.

   OpenUrlCrossRefPubMed
5. 5.↵
   1. Keystone EC,
   2. Kavanaugh AF,
   3. Sharp JT,
   4. Tannenbaum H,
   5. Hua Y,
   6. Teoh LS,
   7. et al.

   Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy. Arthritis Rheum 2004;50:1400–11.

   OpenUrlCrossRefPubMed
6. 6.↵
   1. Klareskog L,
   2. van der Heijde D,
   3. de Jager JP,
   4. Gough A,
   5. Kalden J,
   6. Malaise M,
   7. et al.

   Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 2004;363:675–81.

   OpenUrlCrossRefPubMed
7. 7.↵
   1. Lipsky PE,
   2. van der Heijde DMFM,
   3. St. Clair EW,
   4. Furst DE,
   5. Breedveld FC,
   6. Kalden JR,
   7. et al.

   Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med 2000; 343:1594–602.

   OpenUrlCrossRefPubMed
8. 8.↵
   1. Strand V,
   2. Singh JA

   . Improved health-related quality of life with effective disease-modifying antirheumatic drugs: evidence from randomized controlled trials. Am J Manag Care 2008;14:234–54.

   OpenUrlPubMed
9. 9.↵
   1. Bejarano V,
   2. Reece R,
   3. Quinn M,
   4. Conaghan PG,
   5. Keenan A-M,
   6. Walker D,
   7. et al.

   Job loss in patients with early rheumatoid arthritis can be prevented by early use of the anti-tumor necrosis factor adalimumab: results of the PRevention Of Work Disability (PROWD) study. Arthritis Care Res 2008;59:1467–74.

   OpenUrlCrossRef
10. 10.↵
    1. van Vollenhoven RF,
    2. Cifaldi MA,
    3. Ray S,
    4. Chen N,
    5. Weisman MH

    . Improvement in workplace and household productivity for patients with early rheumatoid arthritis (RA) treated with adalimumab plus methotrexate: work outcomes and their correlations with clinical and radiographic measures from a randomized controlled trial companion study. Arthritis Care Res 2010;62:226–34.

    OpenUrlCrossRef
11. 11.↵
    1. Breedveld FC,
    2. Weisman MH,
    3. Kavanaugh AF,
    4. Cohen SB,
    5. Pavelka K,
    6. van Vollenhoven R,
    7. et al.

    The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate vs. methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006;54:26–37.

    OpenUrlCrossRefPubMed
12. 12.↵
    1. Arnett FC,
    2. Edworthy SM,
    3. Bloch DA,
    4. McShane DJ,
    5. Fries JF,
    6. Cooper NS,
    7. et al.

    The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315–24.

    OpenUrlCrossRefPubMed
13. 13.↵
    1. Prevoo ML,
    2. van ’t Hof MA,
    3. Kuper HH,
    4. van Leeuwen MA,
    5. van de Putte LB,
    6. van Riel PL

    . Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38:44–8.

    OpenUrlCrossRefPubMed
14. 14.↵
    1. Fries JF,
    2. Spitz P,
    3. Kraines RG,
    4. Holman HR

    . Measurement of patient outcome in arthritis. Arthritis Rheum 1980;23:137–45.

    OpenUrlCrossRefPubMed
15. 15.↵
    1. American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines

    . Guidelines for the management of rheumatoid arthritis: 2002 update. Arthritis Rheum 2002;46:328–46.

    OpenUrlCrossRefPubMed
16. 16.↵
    1. St. Clair EW,
    2. van der Heijde DM,
    3. Smolen JS,
    4. Maini RN,
    5. Bathon JM,
    6. Emery P,
    7. et al.

    Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum 2004;50:3432–43.

    OpenUrlCrossRefPubMed
17. 17.↵
    1. Emery P,
    2. Breedveld F,
    3. Hall S,
    4. Durez P,
    5. Chang D,
    6. Robertson D,
    7. et al.

    Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial. Lancet 2008;372:375–82.

    OpenUrlCrossRefPubMed
18. 18.↵
    1. Pincus T,
    2. Kavanaugh A,
    3. Aletaha D,
    4. Smolen J

    . Complexities in defining remission in rheumatic diseases. Clin Exp Rheumatol 2006;24:S-1–6.pmid:17083755

    OpenUrlPubMed
19. 19.↵
    1. Smolen JS,
    2. Han C,
    3. Bala M,
    4. Maini RN,
    5. Kalden JR,
    6. van der Heijde D,
    7. et al.,
    8. ATTRACT Study Group

    . Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: a detailed subanalysis of data from the anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study. Arthritis Rheum 2005;52:1020–30.

    OpenUrlCrossRefPubMed
20. 20.↵
    1. Smolen JS,
    2. Han C,
    3. van der Heijde DM,
    4. Emery P,
    5. Bathon JM,
    6. Keystone E,
    7. et al.,
    8. Active-Controlled Study of Patients Receiving Infliximab for the Treatment of Rheumatoid Arthritis of Early Onset (ASPIRE) Study Group

    . Radiographic changes in rheumatoid arthritis patients attaining different disease activity states with methotrexate monotherapy and infliximab plus methotrexate: the impacts of remission and tumour necrosis factor blockade. Ann Rheum Dis 2009;68:823–7.

    OpenUrlAbstract/FREE Full Text
21. 21.↵
    1. Aletaha D,
    2. Smolen J,
    3. Ward MM

    . Measuring function in rheumatoid arthritis: identifying reversible and irreversible components. Arthritis Rheum 2006;54:2784–92.

    OpenUrlCrossRefPubMed
22. 22.↵
    1. Burmester GR,
    2. Mease P,
    3. Dijkmans BAC,
    4. Gordon K,
    5. Lovell D,
    6. Panaccione R,
    7. et al.

    Adalimumab safety and mortality rates from global clinical trials of six immune-mediated inflammatory diseases. Ann Rheum Dis 2009;68:1863–9.

    OpenUrlAbstract/FREE Full Text